Cannabis based products in multiple sclerosis
On the 1 November 2018, it became legal for doctors to prescribe cannabis based drugs, which occurred with widespread media coverage. But, there are limitations to this ruling, which have not been fully explained to the public, and many neurology departments are receiving queries from patients who are requesting prescriptions for cannabis based drugs from their GP or neurologist. The change in legislation means that medicinal cannabis can only be prescribed by specialists (listed on the GMC specialist register e.g. Consultant neurologists), who have approval from their relevant hospital committees. The change in legislation has not made it possible for GPs (even on private prescription) to prescribe cannabis based medication.
The Academy have an approved letter from UKCPA, which is to aid communication with patients and medical colleagues who are asking about medicinal cannabis.To receive a copy of this letter, please contact info@neurologyacademy.org
The Academy have an approved letter from UKCPA, which is to aid communication with patients and medical colleagues who are asking about medicinal cannabis.To receive a copy of this letter, please contact info@neurologyacademy.orgMore in this video:
https://youtu.be/FVPI0yt_dNI → More videos from this eventListen to this presentation:
→ More podcasts from this eventRelated articles
Encouraging excellence, developing leaders, inspiring change
MS Academy was established five years ago and in that time has accomplished a huge amount. The six different levels of specialist MS training are dedicated to case-based learning and practical application of cutting edge research. Home to national programme Raising the Bar and the fantastic workstream content it is producing, this is an exciting Academy to belong to.